Q1 Earnings Forecast for SAGE Issued By Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Stock analysts at Wedbush issued their Q1 2026 earnings per share estimates for Sage Therapeutics in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico expects that the biopharmaceutical company will post earnings per share of ($0.75) for the quarter. Wedbush has a “Neutral” rating and a $6.00 price target on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.69) EPS and Q4 2026 earnings at ($0.65) EPS.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%.

Other equities analysts have also issued reports about the company. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Piper Sandler cut their target price on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Scotiabank reduced their price target on shares of Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, February 12th. Bank of America initiated coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price objective on the stock. Finally, Canaccord Genuity Group lowered their price target on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday, February 12th. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.81.

Sage Therapeutics Stock Performance

Shares of Sage Therapeutics stock opened at $7.43 on Thursday. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $14.97. The stock has a market capitalization of $456.80 million, a price-to-earnings ratio of -1.13 and a beta of 0.48. The firm has a fifty day moving average of $7.47 and a two-hundred day moving average of $6.72.

Hedge Funds Weigh In On Sage Therapeutics

A number of large investors have recently modified their holdings of SAGE. Caligan Partners LP bought a new stake in Sage Therapeutics during the fourth quarter worth about $16,575,000. Boothbay Fund Management LLC acquired a new stake in shares of Sage Therapeutics in the 4th quarter valued at approximately $7,540,000. State Street Corp grew its stake in shares of Sage Therapeutics by 18.2% in the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares in the last quarter. Federated Hermes Inc. increased its holdings in Sage Therapeutics by 63.7% during the fourth quarter. Federated Hermes Inc. now owns 1,105,779 shares of the biopharmaceutical company’s stock worth $6,004,000 after buying an additional 430,432 shares during the last quarter. Finally, Jane Street Group LLC raised its position in Sage Therapeutics by 103.1% during the fourth quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company’s stock worth $2,509,000 after acquiring an additional 234,528 shares in the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.